FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES

• Main Authors: Assia Konsoulova (Author), Ivan Donev (Author), Nikolay Conev (Author), Sonya Draganova (Author), Nadezhda Petrova (Author), Eleonora Dimitrova (Author), Hristo Popov (Author), Kameliya Bratoeva (Author), Petar Ghenev (Author)
• Format: Book
• Published: Peytchinski Publishing, 2016-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose: Colorectal cancer is the second leading cause of cancer mortality in the USA. According to Bulgarian National Statistics Institute, 2370 colon and 1664 rectal cancer cases were diagnosed in 2012 with total number of patients 29995. Adding bevacizumab to chemotherapy in patients with metasta...